Bedrijfsoverzicht
KORU Medical Systems, Inc. is engaged in the development, manufacturing, and commercialization of subcutaneous infusion solutions, with a primary focus on the United States and international markets for the subcutaneous drug delivery sector. This firm operates within the Healthcare sector, specifically targeting the Medical Instruments & Supplies industry, which implies a specialization in critical equipment for patient care and therapeutic administration. The company's operational scale is defined by a market capitalization of $195.82M, annual revenue of $41.13M, and a workforce comprising 73 employees. These financial dimensions indicate that KORU Medical Systems is a small-cap entity with a niche product offering, positioning it as a specialized player rather than a dominant market leader in the broader healthcare infrastructure landscape.
Financiële gezondheid
The company reported revenue of $41.13M over the trailing twelve months, while simultaneously reporting a net income of $-2,637,926 and an EBITDA of $-2,279,840. The substantial gap between the positive revenue figure and the negative net income reveals a cost structure where operating expenses, such as research and development or selling costs, significantly outweigh gross profits before interest and taxes. Despite the negative earnings, the company maintains a positive free cash flow of $385,832, which suggests a degree of financial flexibility allowing for operational continuity and potential capital allocation without immediate external financing. The margin profile presents a mixed picture, featuring a gross margin of 62.3% which indicates efficient production relative to sales, contrasted by an operating margin of -5.0% and a profit margin of -6.4% that highlight the heavy burden of overhead costs eroding profitability. On the balance sheet, the company holds $8.87M in cash against $3.50M in debt, resulting in a debt-to-equity ratio of 20.51, which indicates a highly conservative capital structure given the low absolute debt levels. Liquidity is robust, evidenced by a current ratio of 2.44, signaling that the company possesses more than double the current assets necessary to cover its short-term liabilities. Return on equity stands at -15.6% and return on assets is -6.7%, metrics that reveal that management is currently unable to generate positive returns on shareholder capital or total assets, reflecting the ongoing losses inherent in the company's growth phase.
Waarderingsbeoordeling
Valuation metrics for KORU Medical Systems show a trailing P/E ratio of N/A due to negative earnings, while the forward P/E is listed at 49.53, implying that the market is pricing in significant future earnings growth to justify the current share price. The price-to-book ratio is 11.44, indicating that the market values the company at a substantial premium over its net asset book value, often seen in biotech or medical device firms with high intangible value or growth potential. Alternative valuation measures include a price-to-sales ratio of 4.76 and an EV/EBITDA of -83.27, which suggest that traditional multiple-based comparisons are skewed by current losses and that valuation relies heavily on revenue multiples and future profitability expectations. The stock has traded between a 52-week high of $6.61 and a 52-week low of $2.08, with the current price sitting at a level that reflects recent volatility but remains well above the annual minimum. The beta value is 0.54, which indicates that the stock's price volatility is less than half that of the broader market, suggesting lower systematic risk relative to a diversified portfolio of large-cap equities.
Growth & Income
Revenue growth year-over-year stands at 23.3%, whereas earnings growth is N/A due to the absence of profitable earnings in the recent period, implying that top-line expansion is occurring without corresponding bottom-line improvement. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, meaning that all generated cash and earnings are retained within the business to fund operations, R&D, or strategic acquisitions rather than being distributed to shareholders. This reinvestment strategy is typical for companies in the early stages of commercialization that prioritize scaling their market presence over providing income to investors. The overall growth and income profile is characterized by strong revenue expansion coupled with negative earnings and no dividend distribution, creating a high-risk, high-reward dynamic focused entirely on future operational turnaround and profitability.